EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSNFUG00015010411
Gene Symbol: EGLN3
3 Cross references
198 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSNFUG00015015277
Gene Symbol: LOC107376137
3 Cross references
212 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSNFUG00015024545
Gene Symbol: LOC107388317
3 Cross references
205 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSNFUG00015005218
Gene Symbol: LOC107384300
3 Cross references
195 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSNFUG00015001542
Gene Symbol: LOC107376805
3 Cross references
197 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSNFUG00015020041
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSNFUG00015009852
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Engrailed Homeobox 1

Ensembl ID : ENSNFUG00015016215
Gene Symbol: EN1
3 Cross references
234 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSNFUG00015009161
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSNFUG00015016792
Gene Symbol: EPHB4B
1 Cross references
160 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSNFUG00015009546
Gene Symbol: EGFR
1 Cross references
215 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSNFUG00015019746
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).